Interestingly, studies employing xenograft prostate tumor models have shown that castrate-resistant prostate cancer (CRPC) tumors that emerge after androgen-ablation therapy, continue to express AR and AR-regulated genes [19]. This evidence concerns the gene AR and prostate carcinoma.